| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | TECH | Common Stock | Sale | -$3.03M | -6.73K | -4.03% | $449.35* | 160K | Jun 17, 2021 | Direct | F1, F2, F3 |
| transaction | TECH | Common Stock | Sale | -$765K | -1.7K | -1.06% | $450.39* | 158K | Jun 17, 2021 | Direct | F1, F3, F4 |
| transaction | TECH | Common Stock | Sale | -$474K | -1.05K | -0.66% | $451.54* | 157K | Jun 17, 2021 | Direct | F1, F3, F5 |
| transaction | TECH | Common Stock | Sale | -$49.3K | -109 | -0.07% | $452.13* | 157K | Jun 17, 2021 | Direct | F1, F3 |
| transaction | TECH | Common Stock | Sale | -$1.16M | -2.58K | -1.64% | $449.09* | 155K | Jun 18, 2021 | Direct | F1, F3, F6 |
| transaction | TECH | Common Stock | Sale | -$147K | -326 | -0.21% | $450.37* | 154K | Jun 18, 2021 | Direct | F1, F3, F7 |
| holding | TECH | Common Stock | 100 | Jun 17, 2021 | By Step-Son | ||||||
| holding | TECH | Common Stock | 100 | Jun 17, 2021 | By Step-Daughter |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| holding | TECH | Stock Options (Right to Buy) | 95.3K | Jun 17, 2021 | Common Stock | 95.3K | $108.49 | Direct | F8 | |||||
| holding | TECH | Stock Options (Right to Buy) | 79.5K | Jun 17, 2021 | Common Stock | 79.5K | $108.49 | Direct | F8 | |||||
| holding | TECH | Stock Options (Right to Buy) | 154K | Jun 17, 2021 | Common Stock | 154K | $106.59 | Direct | F8 | |||||
| holding | TECH | Stock Options (Right to Buy) | 103K | Jun 17, 2021 | Common Stock | 103K | $106.59 | Direct | F8 | |||||
| holding | TECH | Stock Options (Right to Buy) | 117K | Jun 17, 2021 | Common Stock | 117K | $125.05 | Direct | F8 | |||||
| holding | TECH | Stock Options (Right to Buy) | 78.2K | Jun 17, 2021 | Common Stock | 78.2K | $125.05 | Direct | F10 | |||||
| holding | TECH | Restricted Stock Units | 16.9K | Jun 17, 2021 | Common Stock | 16.9K | Direct | F9, F11 | ||||||
| holding | TECH | Stock Options (Right to Buy) | 90.3K | Jun 17, 2021 | Common Stock | 90.3K | $177.32 | Direct | F11 | |||||
| holding | TECH | Stock Options (Right to Buy) | 60.2K | Jun 17, 2021 | Common Stock | 60.2K | $177.32 | Direct | F12 | |||||
| holding | TECH | Restricted Stock Units | 16.9K | Jun 17, 2021 | Common Stock | 16.9K | Direct | F9, F13 | ||||||
| holding | TECH | Stock Options (Right to Buy) | 85.7K | Jun 17, 2021 | Common Stock | 85.7K | $190.41 | Direct | F13 | |||||
| holding | TECH | Stock Options (Right to Buy) | 57.2K | Jun 17, 2021 | Common Stock | 57.2K | $190.41 | Direct | F14 | |||||
| holding | TECH | Restricted Stock Units | 12.9K | Jun 17, 2021 | Common Stock | 12.9K | Direct | F9, F15 | ||||||
| holding | TECH | Stock Options (Right to Buy) | 57.4K | Jun 17, 2021 | Common Stock | 57.4K | $267.87 | Direct | F15 | |||||
| holding | TECH | Stock Options (Right to Buy) | 38.3K | Jun 17, 2021 | Common Stock | 38.3K | $267.87 | Direct | F16 | |||||
| holding | TECH | Stock Options (Right to Buy) | 16.7K | Jun 17, 2021 | Common Stock | 16.7K | $267.87 | Direct | F17 | |||||
| holding | TECH | Stock Options (Right to Buy) | 16.7K | Jun 17, 2021 | Common Stock | 16.7K | $267.87 | Direct | F18 |
| Id | Content |
|---|---|
| F1 | The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021. |
| F2 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $449.00 to $449.94, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F3 | Includes (i) 3,759 shares of restricted stock for which the risk of forfeiture will lapse on August 8, 2021; (ii) 7,527 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on August 7, 2021 and as to 3,763 shares on August 7, 2022; and (iii) 8,586 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2021, August 5, 2022 and August 5, 2023. |
| F4 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $450.075 to $450.95, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F5 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $451.02 to $452.02, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F6 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $449.00 to $449.63, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F7 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $450.37 to $450.625, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F8 | Fully exercisable. |
| F9 | Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. |
| F10 | Options to purchase 19,557 shares vest on each of 8/9/2018, 8/9/2019, 8/9/2020 and 8/9/2021. |
| F11 | Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| F12 | Options to purchase 15,056 shares vest on each of 8/8/2019 and 8/8/2020 and options to purchase 15,055 shares vest on each of 8/8/2021 and 8/8/2022. |
| F13 | Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| F14 | Options to purchase 14,288 shares vest on each of 8/7/2020 and 8/7/2021 and options to purchase 14,287 shares vest on each of 8/7/2022 and 8/7/2023. |
| F15 | Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| F16 | Options to purchase 9,573 shares vest on 8/5/21 and options to purchase 9,574 shares vest on each of 8/5/22, 8/5/23 and 8/5/24. |
| F17 | Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021. |
| F18 | Options to purchase 5,550 shares vest on each of 8/5/21, 8/5/22 and 8/5/23. |